FindTrial
Sign In

Evaluation of Dexmedetomidine for prevention of Etomidate induced Myoclonus.

To study comparative efficacy with three different doses of dexmeditomidine for prevention of etomidate induced myoclonus

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/09/027965
Enrollment
120
Registered
2020-09-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R69- Illness, unspecified Health Condition 2: O- Medical and Surgical

Interventions

Control Intervention1: To Compare Effect Of Three Different Doses Of Dexmedetomidine (0.25ug/kg, 0.5ug/kg, 1ug/kg) over 10 mins On Etomidate (0.3mg/kg) Induced Myoclonus for 60 mins: Elective Cases Fo

Sponsors

Managing Society Dayanand Medical College and Hospital Tagore Nagar Ludhiana
Lead Sponsor
Managing Society Dayanand Medical College and Hospital Tagore Nagar Ludhiana
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: ASA physical status I OR II with BMI <30 Kg/m2 and scheduled for elective surgery under general anaesthesia

Exclusion criteria

Exclusion criteria: . Patients with BMI >30 kg/m2 . Patients with Bradycardia (HR Heart Blocks, on Beta Blockers or Having Impanted Pacemakers . Known Case of Hypoadrenalism or Patients on Steroid medication . H/o Asthma , Chronic Cough or Upper Respiratory Tract Infection Two weeks Prior to Surgery . H/o any Neurological disease. . H/o any Psychiatric disease. . Pregnant and Lactating Patients. . H/o any Drug Allergy. . Patients having Uncontrolled Diabetes or Hypertension. . Patients who have received Benzodiazipines or Opioids within the previous 24 hrs. . Any evidence of Sepsis.

Design outcomes

Primary

MeasureTime frame
The Following Parameters will be statistically analysed: 1)Incidence of Etomidate Induced Myoclonus. 2)Grading of Etomidate Induced Myoclonus. 3)Incidence of Any Adverse Effects.Timepoint: Study drug will be administered over 10 minutes as per group allocation.Once infusion is completed, this time will be labelled as 0 and 0.3mg/Kg Etomidate will be given I/V. Patients will be obeserved for Myoclonus for 2 minutes. Hemodynamics will be recorded every 1 minute for initial 10 minutes and then every 5 minutes till end of 60 minutes.—

Secondary

MeasureTime frame
To find minimum effective dose of etomidate to suppress myoclonusTimepoint: 2 minute after induction—

Countries

India

Contacts

Public ContactDr Richa Jindal

Department of Anesthesia, Dayanand Medical College and Hospital, Tagore Nagar, Ludhiana.

sandeepkundra07@gmail.com09815608241

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026